Open hour: senin - sabtu 09:00:00 - 20:00:00; minggu & tanggal merah tutup
Case presentation : A rare case of bevacizumab-related osteonecrosis of the jaw associated with dental implants [1]

Case presentation : A rare case of bevacizumab-related osteonecrosis of the jaw associated with dental implants [1]

author: Gustavo Maluf, Rogrio Jardim Caldas, Eduardo Rodrigues Fregnani, Paulo Srgio da Silva Santos | publisher: drg. Andreas Tjandra, Sp. Perio, FISID

A 54-year-old Caucasian woman complained of an unpleasant taste and pain in the mouth. Her medical history included breast cancer with metastasis, which was diagnosed in 2007. The patient had no comorbidities and no history of smoking. A radical mastectomy with axillary dissection was performed. The patient had no previous history of radiotherapy of the head and neck or use of bisphosphonates. The patient received bevacizumab (400 mg/16 mL every 2 weeks; 32 infusions in total) from 11 April 2014 to 26 October 2016. Docetaxel (30 mg/m2 on D1 and D15 of the cycle) and carboplatin (386 mg on D1 and D15 of the cycle) infusions were started in April 2014 and suspended in September 2016. The patient’s leukocyte count was 4310 cells/mm3 (segmented neutrophils, 1896/mm3; band neutrophils, 0/mm3). At 28 days following suspension of the cancer treatment, intraoral clinical examination revealed drainage of purulent secretion involving teeth 16, 25, 27, 44, and 47 (Fig. 1). Cone-beam computed tomography (CT) showed the association of hypodense areas with the remaining roots of teeth 16, 25, and 27, and disruption of the lower cortical regions of the maxillary sinus. Hypodense areas could also be seen associated with the roots of teeth 44 and 47 (Fig. 2). The patient did not present with clinical characteristics or radiographic findings to suggest MRONJ, and dental implant was placed on 19 December 2016 (3 months after suspension of her medication). At 54 days after the last dose of bevacizumab, and on completion of 3 months of docetaxel and carboplatin infusions, debridement and dental extractions of teeth 16, 25, 27, 44, and 47 were performed in combination with immediate insertion of Straumann® Bone Level Tapered-BLT® implants (SLActive) in regions of teeth 44, 45, 46, and 47 (Fig. 3). Chlorhexidine 0.12% mouth wash and levofloxacin (Levoxin®) were prescribed 5 days before and after the oral implantation surgery and continued 5 days after the implantation surgery.

Serial posts:


id post:
New thoughts
Me:
search
glossary
en in